The consensus molecular subtypes of colorectal cancer.
Guinney JSage Bionetworks, Seattle, Washington, USA.
Dienstmann RSage Bionetworks, Seattle, Washington, USA.
Wang XLaboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM), Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands.
de Reyniès ALigue Nationale Contre le Cancer, Paris, France.
Schlicker ANetherlands Cancer Institute (NKI), Amsterdam, the Netherlands.
Soneson CSwiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.
Marisa LLigue Nationale Contre le Cancer, Paris, France.
Gerster SSwiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.
Fessler ELaboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM), Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands.
De Sousa E Melo FLaboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM), Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands.
Missiaglia ESwiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.
Ramay HSwiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.
Barras DSwiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.
Homicsko KÉcole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Maru DThe University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA.
Manyam GCThe University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA.
Broom BThe University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA.
Gray JWBiomedical Engineering, Oregon Health Sciences University, Portland, Oregon, USA.
Hanahan DÉcole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Tabernero JVall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
Bernards RNetherlands Cancer Institute (NKI), Amsterdam, the Netherlands.
Friend SHSage Bionetworks, Seattle, Washington, USA.
Laurent-Puig PUniversité Paris Descartes, Paris, France.
Medema JPLaboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM), Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands.
Sadanandam AInstitute of Cancer Research, London, UK.
Wessels LNetherlands Cancer Institute (NKI), Amsterdam, the Netherlands.
Delorenzi MSwiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.
Kopetz SThe University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA.
Vermeulen LLaboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM), Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands.
English
Colorectal cancer (CRC) is a frequently lethal disease with heterogeneous outcomes and drug responses. To resolve inconsistencies among the reported gene expression-based CRC classifications and facilitate clinical translation, we formed an international consortium dedicated to large-scale data sharing and analytics across expert groups. We show marked interconnectivity between six independent classification systems coalescing into four consensus molecular subtypes (CMSs) with distinguishing features: CMS1 (microsatellite instability immune, 14%), hypermutated, microsatellite unstable and strong immune activation; CMS2 (canonical, 37%), epithelial, marked WNT and MYC signaling activation; CMS3 (metabolic, 13%), epithelial and evident metabolic dysregulation; and CMS4 (mesenchymal, 23%), prominent transforming growth factor-β activation, stromal invasion and angiogenesis. Samples with mixed features (13%) possibly represent a transition phenotype or intratumoral heterogeneity. We consider the CMS groups the most robust classification system currently available for CRC-with clear biological interpretability-and the basis for future clinical stratification and subtype-based targeted interventions.